Literature DB >> 7700568

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients.

M Mogi1, M Harada, T Kondo, P Riederer, H Inagaki, M Minami, T Nagatsu.   

Abstract

Interleukin (IL)-1 beta, IL-6, epidermal growth factor (EGF), and transforming growth factor-alpha (TGF-alpha) were measured for the first time in the brain (caudate nucleus, putamen and cerebral cortex) from control and parkinsonian patients by highly sensitive sandwich enzyme immunoassays. The concentrations of IL-1 beta, IL-6, EGF, and TGF-alpha in the dopaminergic, striatal regions were significantly higher in parkinsonian patients than those in controls, whereas those in the cerebral cortex did not show significant differences between parkinsonian and control subjects. Since these cytokines and growth factors may play important roles as neurotrophic factors in the brain, the present results suggest that they may be produced as compensatory responses in the nigrostriatal dopaminergic regions in Parkinson's disease, and may be related, at least in part, to the process of neurodegeneration in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7700568     DOI: 10.1016/0304-3940(94)90508-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  266 in total

1.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

2.  IL-1 family members as candidate genes modulating scrapie susceptibility in sheep: localization, partial characterization, and expression.

Authors:  Ane Marcos-Carcavilla; Jorge H Calvo; Carmen González; Katayoun Moazami-Goudarzi; Pascal Laurent; Maud Bertaud; Hélène Hayes; Anne E Beattie; Carmen Serrano; Jaber Lyahyai; Inmaculada Martín-Burriel; Estefânia Alves; Pilar Zaragoza; Juan J Badiola; Magdalena Serrano
Journal:  Mamm Genome       Date:  2007-01-22       Impact factor: 2.957

3.  The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.

Authors:  P R Mouton; B Kelley-Bell; D Tweedie; E L Spangler; E Perez; O D Carlson; R G Short; R deCabo; J Chang; D K Ingram; Y Li; N H Greig
Journal:  Neurobiol Aging       Date:  2010-11-19       Impact factor: 4.673

4.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

5.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

Review 6.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects.

Authors:  Francisco Arnaldo Viana Lima; Ivan Pinheiro Joventino; Francisca Pinheiro Joventino; Aline Cordeiro de Almeida; Kelly Rose Tavares Neves; Marta Regina do Carmo; Luzia Kalyne Almeida Moreira Leal; Geanne Matos de Andrade; Glauce Socorro de Barros Viana
Journal:  Neurochem Res       Date:  2017-08-31       Impact factor: 3.996

8.  Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

Authors:  Hua-Qing Liu; Wei-Yu Zhang; Xue-Ting Luo; Yang Ye; Xing-Zu Zhu
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 9.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

10.  Autoimmune disease and risk for Parkinson disease: a population-based case-control study.

Authors:  K Rugbjerg; S Friis; B Ritz; E S Schernhammer; L Korbo; J H Olsen
Journal:  Neurology       Date:  2009-09-23       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.